Lumateperone Tosylate is Used for treating schizophrenia, bipolar depression, and bipolar disorder by modulating serotonin and dopamine receptor activity. It was first introduced by Intra-Cellular Therapies Inc in its drug Caplyta on Dec 20, 2019.

Lumateperone Tosylate Patents

Given below is the list of patents protecting Lumateperone Tosylate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Caplyta	US10117867	Methods and compositions for sleep disorders and other disorders	May 27, 2029	Intra-cellular
Caplyta	US10464938	Pharmaceutical compositions comprising ((6bR,10aS)-1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one or pharmaceutically acceptable salts thereof	Mar 12, 2028	Intra-cellular
Caplyta	US10695345	Pharmaceutical capsule compositions comprising lumateperone mono-tosylate	Aug 30, 2039	Intra-cellular
Caplyta	US10960009	Methods of treating schizophrenia and depression	Dec 03, 2034	Intra-cellular
Caplyta	US11026951	Methods of treating bipolar disorder	Dec 03, 2034	Intra-cellular
Caplyta	US11052084	Pharmaceutical capsule compositions comprising lumateperone mono-tosylate	Aug 30, 2039	Intra-cellular
Caplyta	US11690842	Pharmaceutical capsule compositions comprising lumateperone mono-tosylate	Aug 30, 2039	Intra-cellular
Caplyta	US11753419	4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders	Dec 10, 2040	Intra-cellular
Caplyta	US11806348	Methods of treatment using pharmaceutical capsule compositions comprising lumateperone mono-tosylate	Aug 30, 2039	Intra-cellular
Caplyta	US11980617	Methods of treating acute depression and/or acute anxiety	Oct 27, 2039	Intra-cellular
Caplyta	US7183282	Substituted heterocycle fused γ-carbolines	Jun 15, 2020 (Expired)	Intra-cellular
Caplyta	US8598119	Methods and compositions for sleep disorders and other disorders	Dec 28, 2029	Intra-cellular
Caplyta	US8648077	4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals	Dec 01, 2029	Intra-cellular
Caplyta	US9168258	Methods and compositions for sleep disorders and other disorders	May 27, 2029	Intra-cellular
Caplyta	US9199995	4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals	Mar 12, 2029	Intra-cellular
Caplyta	US9586960	4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de] quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms	Mar 12, 2029	Intra-cellular
Caplyta	US9616061	Methods and compositions for sleep disorders and other disorders	May 27, 2029	Intra-cellular
Caplyta	US9956227	Method for the treatment of residual symptoms of schizophrenia	Dec 03, 2034	Intra-cellular
Caplyta	USRE39680	Substituted heterocycle fused gamma-carbolines	Jun 15, 2020 (Expired)	Intra-cellular
Caplyta	USRE48825	4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms	Feb 12, 2029	Intra-cellular
Caplyta	USRE48825	4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms	Mar 12, 2029	Intra-cellular
Caplyta	USRE48839	Methods and compositions for sleep disorders and other disorders	Aug 19, 2033	Intra-cellular

Add above patents to watchlist

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳